Erschienen in:
01.06.2012 | Editorial
Myeloid-derived suppressor cells in sepsis: friend or foe?
verfasst von:
Alex G. Cuenca, Lyle L. Moldawer
Erschienen in:
Intensive Care Medicine
|
Ausgabe 6/2012
Einloggen, um Zugang zu erhalten
Excerpt
Through improvements in supportive care measures over the last few decades, such as those guidelines based on the ‘Surviving Sepsis Campaign’ and early goal-directed therapy trials, we have been able to help most of our patients survive through the initial systemic inflammatory response period [
1,
2]. Unfortunately, a significant portion of patients still have protracted hospital courses and eventually succumb to late nosocomial infections [
3]. These late sepsis-associated morbidities are thought to be related to global host immunosuppression. …